Found 459 clinical trials
![A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving KRYSTEXXA® (pegloticase) (MIRROR Randomized Controlled Trial [RCT])](/media/imagery/230589.svg)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving KRYSTEXXA® (pegloticase) (MIRROR Randomized Controlled Trial [RCT])
The purpose of this study is to obtain information on the safety, tolerability and effectiveness of administering an immunosuppressive therapy (Methotrexate) (MTX) in combination with KRYSTEXXA
- 22 views
- 23 Nov, 2020
- 1 location
Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease
This study will determine if a dexamethasone mouth rinse can reduce the risk of developing oral chronic graft-versus-host disease (cGVHD) in patients who have undergone a bone marrow (stem cell) transplant procedure. cGVHD is a common complication of stem cell transplantation, resulting from the donor cells attacking the transplant recipient's …
- 38 views
- 22 Dec, 2020
- 1 location
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
eltrombopag to standard immunosuppressive therapy for severe aplastic anemia. Eligibility: Individuals at least 2 years of age who have severe aplastic anemia that
- 123 views
- 22 Dec, 2020
- 1 location
A Randomized Trial of Sirolimus (Rapamune) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
, compared with stopping cyclosporine alone. Eligibility: People ages 2 and older with SAA who: Have responded to immunosuppressive therapy that includes
- 61 views
- 22 Dec, 2020
- 1 location
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy
irradiation to suppress immunity and prevent rejection of the donated cells. Infusion of the donated stem cells and umbilical cord cells. Immune suppression with the drugs tacrolimus
- 48 views
- 22 Dec, 2020
- 1 location
Research Study of ATG and Rituximab in Renal Transplantation (RESTARRT)
Research Study of ATG and Rituximab in Renal Transplantation (RESTARRT)
- 1078 views
- 23 Nov, 2020
- 5 locations
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (OPTIMAL)
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (OPTIMAL)
- 244 views
- 23 Nov, 2020
- 5 locations
Haplo-identical Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using Peripheral Blood Stem Cells and Post-Transplant Cyclophosphamide for GVHD Prophylaxis
Background: Severe aplastic anemia (SAA) and myelodysplastic syndrome (MD) cause serious blood problems. Stem cell transplants using bone marrow or blood plus chemotherapy can help. Researchers want to see if using peripheral blood stem cells (PBSCs) rather than bone marrow cells works too. PBSCs are easier to collect and have …
- 57 views
- 22 Dec, 2020
- 1 location
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the complications for these procedures. This might allow more people to have a transplant. Objective: To see if a new transplant regime is effective, safe and well …
- 57 views
- 22 Dec, 2020
- 1 location
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer
- 314 views
- 25 Mar, 2021
- 4 locations